Skip to main content
TipRanks
Go Ultimate75% OFF

Insmed (IM8N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

IM8N Analyst Ratings

Strong Buy
17Ratings
16Buy1Hold0Sell
Based on 17 analysts giving stock ratings to Insmed in the past 3 months

IM8N Stock 12 Month Forecast

CHF160.09â–²(74.64% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is CHF 160.09 with a high forecast of CHF 184.88 and a low forecast of CHF 132.78. The average price target represents a 74.64% change from the last price of CHF 91.67.
Highest Price TargetCHF184.88Average Price TargetCHF160.09Lowest Price TargetCHF132.78

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:IM8N
Price TargetArticle
RBC CapitalCHF163.87buy78.76%UpsideReiterated11/17/26
Morgan StanleyCHF179.00buy95.27%UpsideReiterated11/13/26
Evercore ISICHF142.86buy55.85%UpsideReiterated11/05/26
H.C. WainwrightCHF184.88buy101.68%UpsideInitiated11/04/26
Mizuho SecuritiesCHF129.41→CHF132.78buy44.84%UpsideReiterated11/03/26
BMO CapitalCHF161.35buy76.01%UpsideReiterated11/02/26
BarclaysCHF173.95buy89.76%UpsideReiterated11/02/26
Leerink Partners Analyst forecast on CH:IM8NUnknown AnalystNot RankedLeerink PartnersCHF176.47→CHF166.39buy81.51%UpsideReiterated11/02/26
GuggenheimCHF172.27→CHF168.91buy84.26%UpsideReiterated11/01/26
UBSCHF144.54buy57.68%UpsideReiterated10/30/26
Goldman SachsCHF157.99→CHF163.03buy77.85%UpsideReiterated10/30/26
Roth MKMCHF166.39→CHF171.43buy87.01%UpsideReiterated10/29/26
Raymond JamesCHF157.15→CHF145.38buy58.60%UpsideReiterated10/20/26
Wells FargoCHF142.02buy54.93%UpsideAssigned10/13/26
Wolfe Research―hold―Downgraded10/12/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
PTGXProtagonist Therapeutics
IMUXImmunic
IVAInventiva
PALIPalisade Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months
Jessica Fye
Jessica FyeJ.P. Morgan
Success Rate16/22 ratings generated profit
73%
Average Return
+21.53%

Copying Jessica Fye's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +21.53% per trade.

1 Year
Tiago Fauth
Tiago FauthRaymond James
Success Rate16/18 ratings generated profit
89%
Average Return
+81.37%

Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +81.37% per trade.

2 Years
Jessica Fye
Jessica FyeJ.P. Morgan
Success Rate20/22 ratings generated profit
91%
Average Return
+91.35%

Copying Jessica Fye's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +91.35% per trade.

IM8N Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for IM8N
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy5146424036
Buy81415122
Hold00011
Sell00000
Strong Sell00000
total5960575339

In the current month, IM8N has received 38 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. IM8N average Analyst price target in the past 3 months is 160.09.

IM8N Financial Forecast

CHF-3CHF-2CHF-1CHF0CHF1Q1 2026Q3 2026Q4 2026
HighCHF0.13
ConsensusCHF-0.25
LowCHF-0.75

IM8N Earnings Forecast

Next quarter’s earnings estimate for IM8N is -CHF 0.25 with a range of -CHF 0.75 to CHF 0.13. The previous quarter’s EPS was -CHF 0.39. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF221.7MCHF302.4MCHF383MCHF463.6MCHF544.3MQ1 2026Q3 2026Q4 2026
HighCHF544M
ConsensusCHF507M
LowCHF475M

IM8N Sales Forecast

Next quarter’s sales forecast for IM8N is CHF 507.38M with a range of CHF 474.80M to CHF 544.27M. The previous quarter’s sales results were CHF 440.71M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

IM8N Stock Forecast FAQ

What is CH:IM8N’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is CHF160.09.
What is CH:IM8N’s upside potential, based on the analysts’ average price target?
Insmed has 74.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Insmed a Buy, Sell or Hold?
Insmed has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Insmed’s share price target?
The average share price target for Insmed is CHF160.09. This is based on 17 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF184.88, and the lowest forecast is CHF132.78. The average share price target represents a 74.64% increase from the current price of CHF91.668.
What do analysts say about Insmed?
Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Street analysts.
How can I buy shares of Insmed?
To buy shares of CH:IM8N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.